Payment overview · 2025
General Payments
$1,272.81
67 reported records · 17 companies
Healthcare provider profile · identity verified
Amy Beth Pearson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BUCKHANNON, WV · NPI 1578524195
Verified facts
What the public records show
CMS Open Payments records show Amy Beth Pearson, M.D. received $1,272.81 in general payments during 2025 across 67 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $371.29 | 29.2% | 21 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $131.13 | 10.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $119.45 | 9.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.97 | 8.0% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $101.17 | 8.0% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $79.16 | 6.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.89 | 5.4% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$48.12 | 3.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.32 | 3.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.43 | 2.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.32 | 2.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $31.32 | 2.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.87 | 2.4% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $27.59 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.89 | 1.5% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $14.39 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.50 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,272.81 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $282.85 | 16 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $131.13 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.97 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $101.97 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $101.17 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $88.44 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $79.16 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.89 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.51 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $55.94 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.94 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $48.12 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.43 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 129 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 210 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
210 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 661 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 623 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 163 |
| Simvastatin | Simvastatin | 530 | 136 |
| Metformin Hcl | Metformin Hcl | 467 | 130 |
| Omeprazole | Omeprazole | 448 | 124 |
| Gabapentin | Gabapentin | 424 | 73 |
| Losartan Potassium | Losartan Potassium | 406 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 373 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 82 |
| Meloxicam | Meloxicam | 277 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 83 |
| Furosemide | Furosemide | 245 | 63 |
| Lorazepam | Lorazepam | 211 | 34 |
| Ozempic | Semaglutide | 210 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 206 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 179 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 49 |
| Montelukast Sodium | Montelukast Sodium | 170 | 48 |
| Sertraline Hcl | Sertraline Hcl | 166 | 43 |
| Jardiance | Empagliflozin | 164 | 39 |
| Donepezil Hcl | Donepezil Hcl | 161 | 42 |
| Potassium Chloride | Potassium Chloride | 157 | 47 |
| Tramadol Hcl | Tramadol Hcl | 156 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 46 |
| Alendronate Sodium | Alendronate Sodium | 148 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 142 | 24 |
| Eliquis | Apixaban | 129 | 35 |
| Ezetimibe | Ezetimibe | 123 | 38 |
| Buspirone Hcl | Buspirone Hcl | 108 | 26 |
| Atenolol | Atenolol | 100 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 98 | 30 |
| Trazodone Hcl | Trazodone Hcl | 93 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 12 |
| Famotidine | Famotidine | 92 | 25 |
| Clonazepam | Clonazepam | 91 | 13 |
| Allopurinol | Allopurinol | 80 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 29 |
| Trulicity | Dulaglutide | 74 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 19 |
| Sucralfate | Sucralfate | 71 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 15 |
| Alprazolam | Alprazolam | 67 | suppressed |
| Ibuprofen | Ibuprofen | 65 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 17 |
| Nystatin | Nystatin | 58 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 12 |
| Spironolactone | Spironolactone | 57 | 16 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Chlorthalidone | Chlorthalidone | 56 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Prednisone | Prednisone | 54 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 12 |
| Carvedilol | Carvedilol | 46 | 13 |
| Fluconazole | Fluconazole | 46 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Nifedipine Er | Nifedipine | 46 | 12 |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Memantine Hcl Er | Memantine Hcl | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 33 |
| Novolog Flexpen | Insulin Aspart | 40 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 13 |
| Meclizine Hcl | Meclizine Hcl | 37 | 14 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | 11 |
| Diazepam | Diazepam | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | 11 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 20 |
| Finasteride | Finasteride | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 27 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Repatha Syringe | Evolocumab | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 24 |
| Baclofen | Baclofen | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Estradiol | Estradiol | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Invokana | Canagliflozin | 27 | suppressed |
| Verapamil Sr | Verapamil Hcl | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 11 |
| Cefdinir | Cefdinir | 23 | 20 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Triazolam | Triazolam | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,272.81 · 67 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Briviact, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FFRct, Kerendia, LEQVIO, Leqembi, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, REPATHA, Rybelsus, TRELEGY ELLIPTA, VALTOCO, VOQUEZNA, VRAYLAR, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error